Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 9/20 | 0.60 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20231540 | 0.86 | DRD2 (0.42) | GNAO1HRH3HTR4 | |
| SCHEMBL25444591 | 0.84 | GNAO1 (0.70) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| SCHEMBL7733753 | 0.84 | GNAO1 (0.70) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| SCHEMBL25121970 | 0.84 | GNAO1 (0.70) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| SCHEMBL23767405 | 0.84 | GNAO1 (0.74) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| SCHEMBL20154540 | 0.83 | HRH3 (0.52) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| Fluoride SCHEMBL31318598 | 0.82 | GNAO1 (0.68) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| Fluoride SCHEMBL29251703 | 0.82 | GNAO1 (0.68) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL30330489 | 0.82 | GNAO1 (0.73) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL30330734 | 0.82 | GNAO1 (0.73) | GNAO1GNAI3GNAI1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | GNAO1 91/4885GNAI3 158/4885GNAI1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.